Anaemia and Thrombocytopenia in Patients With Prostate Cancer and Bone Metastases

BMC Cancer. 2010 Jun 13;10:284. doi: 10.1186/1471-2407-10-284.

Abstract

Background: The purpose of this study was to determine the incidence, risk factors and prognostic impact of anaemia and thrombocytopenia in patients with bone metastases (BM) from prostate cancer.

Methods: Retrospective cohort study including 51 consecutive patients treated at a community hospital. Twenty-nine patients (57%) received taxotere after diagnosis of BM.

Results: Haemoglobin (Hb) < or = 12.0 g/dL at BM detection was associated with shorter overall survival. During follow-up, 25 patients (49%) experienced episodes with Hb < 10 g/dL unrelated to side effects of cancer therapy. Fifteen patients required red blood cell transfusion. Median time from diagnosis of BM to Hb < 10 g/dL was 23 months. Median survival from Hb < 10 g/dL was 5.4 months. There was no factor predicting for Hb < 10 g/dL. Five patients (10%) developed thrombocyte (Trc) count <50 x 10(9)/L. All of these had previously received blood transfusion. Median interval from Hb < 10 g/dL to Trc < 50 x 10(9)/L was 2.5 months. Survival after thrombocytopenia was short (3 weeks to 4 months). Haematuria and subdural haematoma were among the causes of death.

Conclusions: We found high rates of significant bone marrow failure in treatment-refractory patients. Both Hb < 10 g/dL and Trc < 50 x 10(9)/L predict for unfavourable survival.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anemia / blood
  • Anemia / etiology*
  • Anemia / mortality
  • Anemia / therapy
  • Antineoplastic Agents / therapeutic use
  • Biomarkers / blood
  • Bone Neoplasms / complications
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / mortality
  • Bone Neoplasms / secondary*
  • Docetaxel
  • Erythrocyte Transfusion
  • Hemoglobins / metabolism
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Norway
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Taxoids / therapeutic use
  • Thrombocytopenia / blood
  • Thrombocytopenia / etiology*
  • Thrombocytopenia / mortality
  • Thrombocytopenia / therapy
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Hemoglobins
  • Taxoids
  • Docetaxel